SCHEMBL329052

SCHEMBL329052

CC(C)CCCS(=O)(=O)O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.46
LMNA P02545 2/20 0.38
BLM P54132 2/20 0.38
PTGS1 P23219 1/20 0.38
PDE4A P27815 1/20 0.38
SLC6A6 P31641 1/20 0.38
CYP2C19 P33261 1/20 0.38
TP53 P04637 1/20 0.37
CA1 P00915 2/20 0.33
S1PR2 O95136 1/20 0.32
S1PR1 P21453 1/20 0.32
S1PR3 Q99500 1/20 0.32
ST6GAL1 P15907 1/20 0.31
GRIA1 P42261 3/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HTT P42858 1/20 0.31
KMT2A Q03164 1/20 0.31
GPBAR1 Q8TDU6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL18008289 0.97 APP (0.44) APPLMNABLMPTGS1PDE4A
SCHEMBL966471 0.97 APP (0.44) APPLMNABLMPTGS1PDE4A
SCHEMBL28621315 0.97 APP (0.44) APPLMNABLMPTGS1PDE4A
Dimethylamine SCHEMBL18008742 0.93 APP (0.41) APPLMNABLMPTGS1PDE4A
SCHEMBL5637565 0.92 APP (0.44) APPLMNABLMPTGS1PDE4A
SCHEMBL2240223 0.91 LMNA (0.54) APPLMNABLMPTGS1PDE4A
SCHEMBL10045748 0.91 LMNA (0.54) APPLMNABLMPTGS1PDE4A
SCHEMBL25355908 0.90 APP (0.42) APPLMNABLMPTGS1PDE4A
SCHEMBL9019490 0.90 APP (0.42) APPLMNABLMPTGS1PDE4A
SCHEMBL8811148 0.90 APP (0.42) APPLMNABLMPTGS1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034124-A1 NOVEL SALTS AND CRYSTALS INTRA CELLULAR THERAPIES INC (US) 2026-02-05 US disclosed
EP-4561569-A2 NOVEL SALTS AND CRYSTALS Intra-Cellular Therapies, Inc. (US) 2025-06-04 EP disclosed
EP-4366733-A1 TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF LANDOS BIOPHARMA, INC. (US) 2024-05-15 EP disclosed
CN-117835980-A Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof 朗多生物制药股份有限公司 2024-04-05 CN disclosed
CN-107209146-B Electrochemical gas sensor and electrolyte for electrochemical gas sensor 德尔格安全股份两合公司 2024-03-12 CN disclosed
WO-2024030835-A2 NOVEL SALTS AND CRYSTALS INTRA-CELLULAR THERAPIES, INC. (US) 2024-02-08 WO disclosed
EP-3927427-B1 LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME NIMMUNE BIOPHARMA INC (US) 2024-02-07 EP disclosed
US-11839476-B2 Bio-electrode composition, bio-electrode, and method for manufacturing a bio-electrode SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-12-12 US disclosed
US-20230357210-A1 NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND HAVING AN OXIME GROUP, AGRICULTURAL OR HORTICULTURAL HERBICIDE COMPRISING THE COMPOUND, AND METHOD FOR USING THE COMPOUND OR THE HERBICIDE NIHON NOHYAKU CO., LTD. (JP) 2023-11-09 US disclosed
US-20230357744-A1 ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2023-11-09 US disclosed
EP-0300278-A2 Process for the preparation of 2-substituted pyrroles BAYER AG (DE) 1989-01-25 EP disclosed
EP-0287890-A1 Substituted pyrroles BAYER AG (DE) 1988-10-26 EP disclosed
US-4678841-A TIN OR TITANIUM HALIDE AND ORGANOSULFONIC ACID AS BINARY CATALYST KURARAY COMPANY, LTD. (JP) 1987-07-07 US disclosed
US-4281116-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1981-07-28 US disclosed
US-4260745-A 3-Halo cephalosporins ELI LILLY AND COMPANY (US) 1981-04-07 US disclosed
US-4252950-A ANTIBIOTICS, BACTERICIDES, FUNGICIDES ELI LILLY AND COMPANY (US) 1981-02-24 US disclosed
US-4208515-A 3-Halo cephalosporins ELI LILLY AND COMPANY (US) 1980-06-17 US disclosed
US-4064343-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1977-12-20 US disclosed
US-4042573-A Sulfonic acid derivatives as promoters for the polymerization of 2-pyrrolidone CHEVRON RESEARCH COMPANY (US) 1977-08-16 US disclosed
US-3962227-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034124-A1 NOVEL SALTS AND CRYSTALS SLC6A4, SLC6A3, HTR2A APP 1522/4885LMNA 2615/4885BLM 2919/4885
US-20230357210-A1 NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND HAVING AN OXIME GROUP, AGRICULTURAL OR HORTICULTURAL HERBICIDE COMPRISING THE COMPOUND, AND METHOD FOR USING THE COMPOUND OR THE HERBICIDE DDT, HDHD5, HPD APP 4266/4885LMNA 4279/4885BLM 2477/4885
US-11839476-B2 Bio-electrode composition, bio-electrode, and method for manufacturing a bio-electrode AFF1, AFF4, AFF2 APP 4136/4885LMNA 2676/4885BLM 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.